Enanta Pharmaceuticals (ENTA) Reports FY2026 Net Loss of $68.2M
Enanta Pharmaceuticals reported FY2026 revenue of $63.0M, down from $65.3M in FY2025, and a net loss of $68.2M, or $2.35 per share, improving from a $81.9M loss in FY2025. The company had $194.5M in cash and expects funding into fiscal 2029. Key catalysts include Q1 2027 LOTUS topline data and 2027 RESOLVE Phase 2b results.
How this was made

The 30-second read
Why it matters
The FY2026 financials and cash runway update the company-specific risk profile. The next tradable catalysts are scheduled clinical readouts (Q1 2027 LOTUS topline and 2027 RESOLVE Phase 2b), so this disclosure mainly affects positioning and financing/dilution expectations rather than immediate trial outcomes.
Market read
Traders can reassess ENTA’s near-term financing risk and valuation sensitivity ahead of later 2027 clinical milestones based on the reported loss and cash runway.
What to watch
The article does not quantify operating cash burn, cost structure drivers, or any updated probability of success for RSV programs, which could materially change how the market interprets the loss and runway.
Background
Enanta is described as a clinical-stage company with declining royalty revenue and an advancing pipeline toward later-stage RSV development.
Ticker impact
Enanta reports FY2026 revenue of $63.0M and a net loss of $68.2M, plus cash of $194.5M and funding expected into fiscal 2029.
Likely downward pressure as investors weigh the larger net loss versus FY2025 and the implications for financing needs, partially offset by the stated funding runway into 2029.
The article provides concrete financial datapoints (revenue, net loss, cash) and a runway statement, but it does not include new clinical trial results or guidance changes beyond the funding expectation.
Market effects
Reinforces typical biotech financing and burn-rate concerns for clinical-stage companies, especially those with royalty revenue decline.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, as the disclosure is company-specific and not tied to a global macro or regulatory event.
Counterpoint
Investors may focus less on the net loss level and more on the narrowing loss trend and the stated funding runway into 2029, viewing the cash position as reducing near-term dilution risk.
Key entities
- companyEnanta Pharmaceuticals
Clinical-stage biotech reporting FY2026 revenue, net loss, cash balance, and expected funding into fiscal 2029.
